611 related articles for article (PubMed ID: 19193571)
1. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.
von Bonin M; Oelschlägel U; Radke J; Stewart M; Ehninger G; Bornhauser M; Platzbecker U
Transplantation; 2008 Sep; 86(6):875-9. PubMed ID: 18813113
[TBL] [Abstract][Full Text] [Related]
4. B-cell involvement in chronic graft-versus-host disease.
Kapur R; Ebeling S; Hagenbeek A
Haematologica; 2008 Nov; 93(11):1702-11. PubMed ID: 18728020
[TBL] [Abstract][Full Text] [Related]
5. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
6. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
Kim SS
Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
8. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease.
Ilhan O; Arat M; Arslan O; Ayyildiz E; Sanli H; Beksac M; Ozcan M; Gürman G; Akan H
Transfus Apher Sci; 2004 Jun; 30(3):185-7. PubMed ID: 15172621
[TBL] [Abstract][Full Text] [Related]
10. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory chronic GVHD with rituximab: a GITMO study.
Zaja F; Bacigalupo A; Patriarca F; Stanzani M; Van Lint MT; Filì C; Scimè R; Milone G; Falda M; Vener C; Laszlo D; Alessandrino PE; Narni F; Sica S; Olivieri A; Sperotto A; Bosi A; Bonifazi F; Fanin R;
Bone Marrow Transplant; 2007 Aug; 40(3):273-7. PubMed ID: 17549053
[TBL] [Abstract][Full Text] [Related]
12. Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.
Schroeder T; Haas R; Kobbe G
Expert Rev Hematol; 2010 Oct; 3(5):633-51. PubMed ID: 21083479
[TBL] [Abstract][Full Text] [Related]
13. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.
van Dorp S; Pietersma F; Wölfl M; Verdonck LF; Petersen EJ; Lokhorst HM; Martens E; Theobald M; van Baarle D; Meijer E; Kuball J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):671-8. PubMed ID: 19450751
[TBL] [Abstract][Full Text] [Related]
14. Chronic graft versus host disease of oral mucosa: review of available therapies.
Imanguli MM; Pavletic SZ; Guadagnini JP; Brahim JS; Atkinson JC
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Feb; 101(2):175-83. PubMed ID: 16448918
[TBL] [Abstract][Full Text] [Related]
15. Immune modulation and chronic graft-versus-host disease.
Soiffer R
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S66-S69. PubMed ID: 18724307
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
[TBL] [Abstract][Full Text] [Related]
17. Chronic graft-versus-host disease.
Cutler C; Antin JH
Curr Opin Oncol; 2006 Mar; 18(2):126-31. PubMed ID: 16462180
[TBL] [Abstract][Full Text] [Related]
18. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
[TBL] [Abstract][Full Text] [Related]
19. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation.
Wechalekar A; Cranfield T; Sinclair D; Ganzckowski M
Clin Lab Haematol; 2005 Aug; 27(4):247-9. PubMed ID: 16048492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
